Antares signs fourth deal with Teva, to develop pen injector
JERUSALEM and EWING, N.J. Antares Pharma and Teva have signed their fourth deal, this time Antares will develop and supply a new disposable pen injector for use with two patient-administered pharmaceutical products of Teva, which as of yet are undisclosed, according to published reports.
Antares has estimated a $500 million market for each drug when they hit the market in the second half of 2011 and 2012.
Under the deal, Antares will receive an upfront cash payment, as well as milestone fees, device sales and royalties on net sales of the combined drug/device product from Pfizer. Antares will also retain the rights to the new injector pen for use with other pharmaceutical and biological products not covered by the agreement.
“These potential new products contribute further confidence to our sales ramp up and royalty growth plans with four new product introductions possible between 2008 through 2012,” said Antares chief executive officer Jack Stover
Internet pharmacies make false claims regarding certification
SOUTH FLORIDA Federal regulators are receiving complaints from the Better Business Bureau and other professional groups after discovering that some Internet pharmacies are falsely claiming to be certified by their organizations, according to South Florida’s Sun-Sentinel.
The pharmacies are stating that they are located in Canada and are therefore offering cheaper prices on drugs to its customers, many of whom are Florida’s elderly. Customers started complaining after they wither did not receive their medications or they got drugs that appeared questionable.
One of the companies that the Internet pharmacies claim to be certified by is PharmacyChecker.com. Over the last 18 months, PharmacyChecker has received about 100 complaints from customers who thought they certified the websites.
The Internet pharmacies are using fake logos and phone numbers to make them appear certified and legitimate to customers. The Canadian International Pharmacy Association, which has 25 member pharmacies that are government-licensed, has also been receiving several calls a week from American consumers about not receiving shipments from sites they thought were CIPA-approved.
The Federal Bureau of Investigation has started a special investigation of Internet pharmacy practices, including the trademark violations and other issues.
Amylin launches SymlinPen for Type 2 diabetes
SAN DIEGO Amylin Pharmaceuticals has released its new prescription device, the SymlinPen 120 and 60 pen-injector devices for administering the blood sugar controlling drug Symlin. The new devices feature simple, fixed dosing to improve mealtime glucose control.
The SymlinPen 120 features fixed dosing to deliver 60 or 120 micrograms of Symlin per dose. The SymlinPen 60 features fixed dosing to deliver 15, 30, 45, or 60 micrograms of Symlin per dose. Both pen-injector devices can be conveniently stored at room temperature not to exceed 86 degrees F after first use.
“Symlin offers enhanced blood glucose control with potential weight loss for patients with diabetes using mealtime insulin, enabling them to do more to manage their diabetes,” said Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals. “The convenience of the new SymlinPen with simple, fixed dosing will make it easier for these patients using multiple daily injections to start and stay with Symlin.”